5 European Projects Found
Searched on 125080 European Projects
FINISHED
Drug Disease Model Resources (DDMORE)
Start date: Mar 1, 2011, End date: Aug 31, 2016,
Model based-drug development (MBDD) is accepted as a vital approach in understanding patient risk/benefit and attrition. At the core of MBDD lies Modelling and Simulation (M&S), a technology providing the basis for informed, quantitative decision-making.M&S facilitates the continuous integration of available information related to a drug or disease into constantly-evolving mathematical models capa ...
Read Project
28
Partners Participants
FINISHED
Mucus Permeating Nanoparticulate Drug Delivery Systems (ALEXANDER)
Start date: Apr 1, 2012, End date: Mar 31, 2016,
The objective of the ALEXANDER project is the identification of novel strategies (e.g., proteolytic enzyme strategy, thiomer strategy, zeta potential changing systems, SNEDDS strategy) and the optimization of existing strategies (e.g., disulfide breaking strategy and slippery surface strategy) for the efficient transport of nanocarriers through the mucus gel layer (e.g., intestinal, nasal, ocular, ...
Read Project
20
Partners Participants
FINISHED
Targeted delivery for liver cancer treatment (HEPTAG EXCHANGE)
Start date: Jan 1, 2012, End date: Dec 31, 2015,
The Liver cancer drugs market is expected to become an active ground for competition in the future. According to recent market analysis, the liver cancer market in 2009 was valued at approximately US$0.4bn, indicating a growth rate of 27.1% between 2001 and 2009. It is estimated that the liver cancer market in 2017 will be $1.2bn, with a compound annual growth rate (CAGR) of 15.5% between 2009 an ...
Read Project
3
Partners Participants
FINISHED
New Therapeutics Strategies for the Treatment of Pediatric Brain Tumors (PEDIAVIR)
Start date: Apr 1, 2011, End date: Mar 31, 2015,
High-risk pediatric brain tumors constitute the leading cause of cancer death in children and despite the improvement of diagnostic and therapeutic approaches children with these malignancies have a very poor prognosis. Thus, it is clear that the management of these malignancies is suboptimal and novel targeted therapeutic strategies are required. Recently, a cancer stem cell population has been f ...
Read Project
2
Partners Participants
FINISHED
Augmenting PBGD expression in the liver as a Novel Gene therapy for Acute Intermittent Porphyria (AIPGENE)
Start date: Jan 1, 2011, End date: Oct 31, 2014,
Acute intermittent porphyria (AIP) is a rare genetic disease in which mutations in the porphobilinogen deaminase (PBGD) gene produce insufficient activity of a protein necessary for heme synthesis. This leads to an accumulation of toxic intermediates resulting in a wide variety of problems including acute, severe abdominal pains, psychiatric and neurological disorders, and muscular weakness. Acute ...
Read Project
